European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"A head-to-head prospective comparative analysis of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT/CT in central nervous system metastases of neuroblastoma and ganglioneuroblastoma.","authors":"Siqi Li,Ziang Zhou,Xiaoya Wang,Yanfeng Xu,Wei Wang,Jun Liu,Jigang Yang","doi":"10.1007/s00259-025-07440-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07440-7","url":null,"abstract":"PURPOSETo assess and compare the diagnostic performance of Gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography (68Ga-DOTATATE PET/CT) and Iodine-123 metaiodobenzylguanidine single photon emission computed tomography/computed tomography (123I-MIBG SPECT/CT) in detecting central nervous system (CNS) metastases of neuroblastoma (NB) and ganglioneuroblastoma (GNB), as well as to evaluate their impact on therapeutic management.METHODSThis prospective study enrolled 41 patients with NB and GNB who were suspected of having CNS metastases. All patients underwent paired 123I-MIBG SPECT/CT and 68Ga-DOTATATE PET/CT imaging within 1 week (median: 3 days; range: 1-7 days). The diagnostic performance of the two imaging modalities was assessed and compared on a per-patient, per-lesion and per-region basis. Furthermore, the differences in patient characteristics between groups with and without changes in clinical management decisions were analyzed. Group differences were evaluated using the independent samples t-test, χ2 test, Fisher's exact test, and Mann-Whitney U test.RESULTS40 patients (40/41, 98%) were confirmed with CNS metastases. The mean age at CNS metastases was 63 months (range: 8-122 months). 68Ga-DOTATATE PET/CT exhibited superior performance compared with 123I-MIBG SPECT/CT in detecting CNS metastases on a per-patient, per-lesion and per-region basis. Additionally, the results of 68Ga-DOTATATE PET/CT led to changes in clinical management in 51% (21/41) of patients, primarily due to new or unexpected findings compared with those obtained using 123I-MIBG SPECT/CT.CONCLUSIONS68Ga-DOTATATE PET/CT demonstrated excellent diagnostic performance in NB and GNB patients with CNS metastases. Moreover, the findings from 68Ga-DOTATATE PET/CT led to a modification of the therapeutic management in 51% of patients.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"82 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144594442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ImmunoPET imaging of c-Met using a nanobody-based tracer [68Ga]Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma models and non-human primates.","authors":"Xinyao Sun,Qi Yang,Lele Song,Youlan Lei,Wenpeng Huang,Zhao Chen,Yongkang Qiu,Lei Kang,Tianyao Wang","doi":"10.1007/s00259-025-07441-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07441-6","url":null,"abstract":"PURPOSEPancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer, with high malignancy and poor prognosis. The cellular mesenchymal-epithelial transition factor (c-Met) is overexpressed in 84% of PDAC and plays a critical role in tumor progression, which is closely associated with poor patient outcomes. In this study, a new 68Ga-labeled nanobody ([68Ga]Ga-NOTA-PFCM01) was developed for the visualization of c-Met in PDAC models.METHODSThe Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) data were utilized to assess MET expression and overall survival in patients with different cancers. By immunizing an alpaca with recombinant human c-Met, three clones of nanobodies were screened, and the binding affinity was tested by bio-layer interferometry (BLI). The binding epitope of the nanobodies and c-Met was predicted by AlphaFold3. c-Met expression in human PDAC cell lines was evaluated using western blot, flow cytometry, and confocal microscopy. NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) chelator was used to label the nanobodies with 68Ga. PET imaging, semiquantitative uptake, and biodistribution research were carried out in tumor xenografts. Histological staining was performed on tumor tissues to characterize the expression of c-Met. In addition, PET imaging in non-human primates was performed to assess pharmacokinetics and biodistribution of the nanobody.RESULTSBased on TCGA and GTEx data, MET expression in pancreatic adenocarcinoma (PAAD) is significantly higher than that in normal tissues (P < 0.001). Patients with high MET expression have lower overall survival rates than those with low MET expression. c-Met expression was the highest in BXPC-3 cells but the lowest in MIA PaCa-2 cells, which were set as the positive and negative models respectively. PFCM01 was screened and selected with an excellent binding property with the KD value of 0.16 nM. The radiochemical purity (RCP) of [68Ga]Ga-NOTA-PFCM01 was high, with good in vivo and in vitro stability. Semiquantitative analysis of small animal positron emission tomography/computed tomography (PET/CT) imaging demonstrated significantly higher tumor uptake in BXPC-3 tumors at 2 h post-injection (2.31 ± 0.02%ID/g) than control groups. Ex vivo biodistribution also showed a high uptake of BXPC-3 tumors (1.90 ± 0.59%ID/g) than others, which was further verified the PET imaging results. Histological staining showed high expression of c-Met in BXPC-3 but low in MIA PaCa-2 tumor tissues. In healthy cynomolgus monkeys, PET imaging revealed rapid renal excretion of [68Ga]Ga-NOTA-PFCM01. No significant radioactive uptake was observed in the liver, stomach, intestines, pancreas, or muscles, indicating its favorable pharmacokinetics and translational potential.CONCLUSIONS[68Ga]Ga-NOTA-PFCM01 showed a specific and high tumor uptake in c-Met-positive PDAC models, providing a noninvasive method to assess c-Met expression. Besides, it demonstrated good pharmac","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"89 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144586584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging based biophysical changes of striatum closely associated with cognitive impairment in childhood self-limited epilepsy with centrotemporal spikes.","authors":"Congcong Yu,Jing Wang,Chentao Jin,Daoyan Hu,Xiaofeng Dou,Xiaohui Zhang,Yuan Sun,Shufang Qian,Qiong Yao,Jianhua Feng,Yan Zhong,Mei Tian,Hong Zhang,Rui Zhou","doi":"10.1007/s00259-025-07397-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07397-7","url":null,"abstract":"PURPOSEThis study aimed to investigate the functional role of striatum in cognitive impairment of self-limited epilepsy with centrotemporal spikes (SeLECTS) patients using 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) and structural magnetic resonance imaging (sMRI).METHODSForty-three patients with SeLECTS (24 typical and 19 atypical) who underwent [18F]FDG PET/CT, 3D-T1WI MRI and neuropsychological assessment were prospectively enrolled. Twenty children with extracranial tumors and twenty healthy children were included as the PET control and MRI control, respectively. Glucose metabolism of brain regions was obtained by measuring standardized uptake value ratio (SUVR) of PET images. Brain structural alterations were derived from MRI image by measuring nuclei volume. Correlation analysis was performed to investigate the relationship among glucose metabolism, brain structural alterations and cognitive function.RESULTSCompared with typical SeLECTS and control group, atypical SeLECTS patients had inferior intelligence quotient (IQ). PET image analysis presented significantly reduced SUVR in bilateral putamen and pallidum of SeLECTS patients. Specifically, atypical SeLECTS had the lowest SUVR of bilateral putamen and pallidum. MRI image analysis showed markedly reduced volume of left putamen and bilateral pallidum in atypical SeLECTS and enlarged volume of left pallidum in typical SeLECTS. Correlation analysis showed that altered SUVR and volume in lenticula were significantly associated with cognitive impairment.CONCLUSIONThis study presented the first imaging findings that cognitive impairment in both atypical and typical SeLECTS patients is highly correlated with glucose metabolism and volume of lenticula, especially in the pallidum, providing further understanding for cognitive impairment of SeLECTS.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144586512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis.","authors":"B L Heesterman,M Peters,D E Oprea-Lager,A J A T Braat,I G Schoots,C C Loeff,P J van Leeuwen,R C N van den Bergh,D A Palma,K K H Aben,W S C Eppinga","doi":"10.1007/s00259-025-07431-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07431-8","url":null,"abstract":"PURPOSETo evaluate the effects of prostate-specific membrane antigen (PSMA) PET/CT use for primary staging on nationwide stage-specific prostate cancer (PCa) incidence rates and treatment patterns.METHODSFor this population-based cohort study, all men diagnosed with PCa in the Netherlands from 2010 to 2023 were identified in the Netherlands Cancer Registry. Year of diagnosis was used as proxy measure for PSMA PET/CT availability and use for primary staging. Overall and stage-specific European age-standardized incidence rates (ESR) and estimated annual percentages change (EAPC) were calculated. Among patients with ≥ 1 high-risk feature, logistic regression was performed to assess the association between year of diagnosis and detection of pelvic lymph node and/or distant metastases. Exploratory analyses were conducted to assess changes in treatment.RESULTSFrom 2010 to 2023, the ESR of PCa declined slightly (EAPC=-0.2%, p = 0.64). Meanwhile, the ESR of pelvic node-positive only and distant metastatic PCa increased (EAPC = 4.6% [p < 0.001] and 4.1% [p < 0.001]). Patients with ≥ 1 high-risk feature were more often diagnosed with pelvic lymph node and/or distant metastases in the years with increasing (OR = 1.33) and widespread (OR = 1.65) access compared to the period with limited access to PSMA PET/CT for primary staging. Meanwhile, the proportion of patients that received systemic therapy increased from 38.7 to 42.0% (OR = 1.15).CONCLUSIONThe implementation of PSMA PET/CT in clinical practice, appears to be associated with a substantial stage shift towards pelvic node-positive and distant metastatic PCa. Exploratory analyses also suggest more frequent treatment with palliative, rather than curative intent. Further research is needed to evaluate effects on clinical outcomes.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"12 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144578620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI lesion tracking in PET/CT imaging: a proposal for a Siamese-based CNN pipeline applied to PSMA PET/CT scans.","authors":"Stefan P Hein,Manuel Schultheiss,Andrei Gafita,Raphael Zaum,Farid Yagubbayli,Robert Tauber,Isabel Rauscher,Matthias Eiber,Franz Pfeiffer,Wolfgang A Weber","doi":"10.1007/s00259-025-07426-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07426-5","url":null,"abstract":"PURPOSEAssessing tumor response to systemic therapies is one of the main applications of PET/CT. Routinely, only a small subset of index lesions out of multiple lesions is analyzed. However, this operator dependent selection may bias the results due to possible significant inter-metastatic heterogeneity of response to therapy. Automated, AI-based approaches for lesion tracking hold promise in enabling the analysis of many more lesions and thus providing a better assessment of tumor response. This work introduces a Siamese CNN approach for lesion tracking between PET/CT scans.METHODSOur approach is applied on the laborious task of tracking a high number of bone lesions in full-body baseline and follow-up [68Ga]Ga- or [18F]F-PSMA PET/CT scans after two cycles of [177Lu]Lu-PSMA therapy of metastatic castration resistant prostate cancer patients. Data preparation includes lesion segmentation and affine registration. Our algorithm extracts suitable lesion patches and forwards them into a Siamese CNN trained to classify the lesion patch pairs as corresponding or non-corresponding lesions.RESULTSExperiments have been performed with different input patch types and a Siamese network in 2D and 3D. The CNN model successfully learned to classify lesion assignments, reaching an accuracy of 83 % in its best configuration with an AUC = 0.91. For corresponding lesions the pipeline accomplished lesion tracking accuracy of even 89 %.CONCLUSIONWe proved that a CNN may facilitate the tracking of multiple lesions in PSMA PET/CT scans. Future clinical studies are necessary if this improves the prediction of the outcome of therapies.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"21 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144578622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [¹⁸F]flortaucipir imaging: TAU-SPEX.","authors":"Emma M Coomans, Bastiaan van Tol, Colin Groot, Ruben Smith, Sebastian Palmqvist, Erik Stomrud, Michael J Pontecorvo, Sergey Shcherbinin, Ian Kennedy, Vikas Kotari, Wiesje M van der Flier, Yolande A L Pijnenburg, Niklas Mattsson-Carlgren, Oskar Hansson, Elsmarieke van de Giessen, Rik Ossenkoppele","doi":"10.1007/s00259-025-07434-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07434-5","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TSPO circadian pattern: a test-retest study of [¹¹C]ER176.","authors":"Quentin Finn, Paolo Zanotti-Fregonara, Meixiang Yu, Masahiro Fujita, Joseph C Masdeu, Belen Pascual","doi":"10.1007/s00259-025-07429-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07429-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging P-glycoprotein function at the blood-brain barrier in drug-resistant epilepsy using [11C]metoclopramide.","authors":"Louise Breuil,Inès Arino,Myriam El Biali,Sebastian Rodrigo,Matthias Jackwerth,Severin Mairinger,Antoine Pinon,Delphine Taussig,Oliver Langer,Nicolas Tournier,Ekaterina Pataraia,Viviane Bouilleret","doi":"10.1007/s00259-025-07437-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07437-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"27 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144533461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic utility of 18F-FDG PET/MRI with intravoxel incoherent motion imaging in nasopharyngeal carcinoma.","authors":"Sheng-Chieh Chan,Shu-Hang Ng,Chih-Hua Yeh,Yu-Chun Lin,Chien-Yu Lin,Jen-Hung Wang,Nai-Ming Cheng,Shih-Hsin Chen,Kai-Ping Chang,Jason Chia-Hsun Hsieh","doi":"10.1007/s00259-025-07425-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07425-6","url":null,"abstract":"PURPOSEIntravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) enhances tissue diffusion assessment by differentiating true molecular diffusion from microvascular perfusion, surpassing conventional DWI. This prospective study assessed the prognostic utility of 18F-FDG PET/MRI with IVIM imaging in patients with primary nasopharyngeal carcinoma (NPC).METHODSWe prospectively enrolled 148 patients with primary NPC who underwent pretreatment PET/MRI. Quantitative parameters derived from IVIM-DWI, dynamic contrast-enhanced MRI (DCE-MRI), and 18F-FDG PET were analyzed for their associations with overall survival (OS) and recurrence-free survival (RFS).RESULTSIVIM-derived minimal true diffusion coefficient (Dmin) and perfusion-related diffusion coefficient (D*) were correlated with RFS (p = 0.018 and 0.043, respectively), outperforming the apparent diffusion coefficient (ADC; p = 0.946). Univariate analysis identified age, tumour stage, T classification, primary tumour standardized uptake value (SUVt), nodal SUV (SUVn), and total lesion glycolysis (TLG) as significant OS predictors. Significant predictors of RFS included Epstein-Barr virus DNA titer, SUVn, DCE-MRI parameters (Kep and Ve), and IVIM parameters (D* and Dmin). In multivariate analysis, age, SUVt, and TLG were independent OS prognostic factors, whereas SUVn, Kep, Dmin (p = 0.009), and Ve (p = 0.012) independently predicted RFS. Prognostic models incorporating the PET/MRI imaging biomarkers showed a significantly higher integrated AUC and Harrell's C-index than the TNM staging system alone.CONCLUSIONIntegrated PET/MRI with IVIM imaging enables simultaneous quantification of water molecule diffusion, tumor microvascular perfusion, and glucose metabolism in NPC, yielding complementary imaging biomarkers that demonstrate superior prognostic value compared to conventional TNM staging.TRIAL REGISTRATIONClinicalTrials.gov (NCT03429868), retrospectively registered on February 6, 2018.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"23 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144533463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.","authors":"Maximilian J Mair, Sabrina Hartenbach, Erwin Tomasich, Sybren L N Maas, Sarah A Bosch, Georg Widhalm, Franziska Eckert, Felix Sahm, Johannes A Hainfellner, Markus Hartenbach, Anna S Berghoff, Matthias Preusser, Nathalie L Albert","doi":"10.1007/s00259-025-07075-8","DOIUrl":"10.1007/s00259-025-07075-8","url":null,"abstract":"<p><strong>Purpose: </strong>High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce.</p><p><strong>Methods: </strong>CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival.</p><p><strong>Results: </strong>Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2%), and FAP expression in 15/58 (25.9%) evaluable samples, with HER2 and HER3 expression in one specimen each (1.7%). Membranous SSTR2a expression was strong in 18 (32.7%), intermediate in 12 (21.8%), and weak in 11 (20.0%) samples. While SSTR2a expression was more homogenous and mainly seen in regions with higher cellularity, FAP immunoreactivity was predominantly seen in tumour stroma and regions of lower cellularity. SSTR2a immunoreactivity was associated with TRAF7 wildtype status (p = 0.034). FAP expression was more frequent in meningiomas of CNS WHO grade 3 (vs. CNS WHO 2; p < 0.001), and samples with NF2 mutations (p = 0.032) or CDKN2A/B deletions (p = 0.013) compared to wildtype. FAP and SSTR2a expression (present vs. absent) were not associated with overall survival (p > 0.05).</p><p><strong>Conclusion: </strong>SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy design.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2771-2781"},"PeriodicalIF":8.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}